In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

1. (original) A compound of formula (1):



(1)

wherein:

Z is CH or nitrogen;

R^4 and R^5 together are either –S-C(R^6)=C(R^7)- or –C(R^7)=C(R^6)-S- ;

R^6 and R^7 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy and (1-4C)alkanoyl;

A is phenylene or heteroarylene;

n is 0, 1 or 2;

R^1 is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, *N*-(1-4C)alkylcarbamoyl, *N*,*N*-((1-4C)alkyl)$_2$carbamoyl, sulphamoyl, *N*-(1-4C)alkylsulphamoyl, *N*,*N*-((1-4C)alkyl)$_2$sulphamoyl, -S(O)$_b$(1-4C)alkyl (wherein b is 0,1,or 2), -OS(O)$_2$(1-4C)alkyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (1-4C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy and -NHSO$_2$(1-4C)alkyl;

or, when n is 2, the two R^1 groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring, optionally containing 1 or 2 heteroatoms independently selected from O, S and N, and optionally being substituted by one or two methyl groups;

r is 1 or 2; and when r is 1 the group



is a substituent on carbon (2) and when r is 2 (hereby forming a six membered ring) the same group is a substituent on carbon (2) or on carbon (3);

Y is selected from $-C(O)R^2$, $-C(O)OR^2$, $-C(O)NR^2R^3$, -(1-4C)alkyl [optionally substituted by 1 or 2 substituents independently selected from hydroxy, $-C=NR^2$, (1-4C)alkoxy, aryloxy, heterocyclyloxy, $-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-O-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-NR^2R^3$, $-N(OH)R^2$, $-NR^2C(=O)R^2$, $-NHOHC(=O)R^2$, $-SO_2NR^2R^3$, $-N(R^2)SO_2R^2$, aryl and heterocyclyl], -C(O)NOH, -C(O)NSH, -C(N)OH, -C(N)SH, $-SO_2H$, $-SO_3H$, $-SO_2N(OH)R^2$, -(2-4C)alkenyl, $-SO_2NR^2R^3$, -(1-4C)alkylC(O)R^2, -(1-4C)alkylC(O)OR^2, -(1-4C)alkylSC(O)R^2, -(1-4C)alkylOC(O)R^2, - (1-4C)alkylC(O)NR^2R^3 , -(1-4C)alkylOC(O)OR^2, -(1-4C)alkylN(R^2)C(O)OR^2, -(1-4C)alkylN(R^2)C(O)NR^2R^3, -(1-4C)alkylOC(O)NR^2R^3, (3-6C)cycloalkyl (optionally substituted by 1 or 2 R^8), aryl, heterocyclyl (wherein the heterocyclic ring is linked by a ring carbon atom), -(1-4C)alkylSO_2(2-4C)alkenyl and $-S(O)_cR^2$ (wherein c is 0, 1 or 2);

R^2 and R^3 are independently selected from hydrogen, -O(1-4C)alkyl, -S(1-4C)alkyl, -N(1-4C)alkyl, heterocyclyl, aryl, and (1-4C)alkyl [optionally substituted by 1 or 2 R^8 groups]; or

wherein NR^2R^3 may form a 4 to 7 membered saturated, partially saturated or unsaturated ring, optionally containing 1, 2 or 3 additional heteroatoms independently selected from N, O and S (provided there are no O-O, O-S or S-S bonds), wherein any $-CH_2-$ may optionally be replaced by –C(=O)-, and any N or S atom may optionally be oxidised to form an N-oxide or SO or SO_2 group respectively, and wherein the ring is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, (1-4C)alkyl, hydroxy, (1-4C)alkoxy and (1-4C)alkyl$S(O)_b$- (wherein b is 0, 1 or 2);

R^8 is independently selected from hydrogen, hydroxy, (1-4C)alkyl, (2-4C)alkenyl, (1-4C)alkoxy, cyano((1-4C))alkyl, amino((1-4C))alkyl [optionally substituted on nitrogen by 1 or 2 groups selected from (1-4C)alkyl, hydroxy, hydroxy((1-4C))alkyl, dihydroxy((1-4C))alkyl, $-CO_2$(1-4C)alkyl, aryl and aryl((1-4C))alkyl], halo((1-4C))alkyl, dihalo((1-4C))alkyl, trihalo((1-4C))alkyl, hydroxy((1-4C))alkyl, dihydroxy((1-4C))alkyl, (1-4C)alkoxy(1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkyl, hydroxy(1-4C)alkoxy, 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, aryl, heterocyclyl, (heterocyclyl)(1-4C)alkyl, (3-7C)cycloalkyl (optionally substituted with 1 or 2 hydroxy groups, (1-4C)alkyl or $-CO_2$(1-4C)alkyl), (1-4C)alkanoyl, (1-4C)alkyl$S(O)_b$- (wherein b is 0, 1 or 2), (3-6C)cycloalkyl$S(O)_b$- (wherein b is 0, 1 or 2), aryl$S(O)_b$- (wherein b is 0, 1 or 2), heterocyclyl$S(O)_b$- (wherein b is 0, 1 or 2), benzyl$S(O)_b$- (wherein b is 0, 1 or 2), (1-4C)alkyl$S(O)_c$(1-4C)alkyl- (wherein c is 0, 1 or 2), -N(OH)CHO, $-C(=N-OH)NH_2$, -C(=N-OH)NH(1-4C)alkyl, -C(=N-OH)N((1-4C)alkyl)$_2$, -C(=N-OH)NH(3-6C)cycloalkyl, -C(=N-OH)N((3-6C)cycloalkyl)$_2$, -COCOOR^9, -C(O)N(R^9)(R^{10}), -NHC(O)R^9, $-C(O)NHSO_2$((1-4C)alkyl), $-NHSO_2R^9$, (R^9)(R^{10})NSO_2-, $-COCH_2OR^{11}$, $-COCH_2OH$,

$(R^9)(R^{10})N$-, -$COOR^9$, -CH_2OR^9, –CH_2COOR^9 , –CH_2OCOR^9, -$CH_2CH(CO_2R^9)OH$, -$CH_2C(O)NR^9R^{10}$, -$(CH_2)_wCH(NR^9R^{10})CO_2R^{9'}$ (wherein w is 1, 2 or 3), and -$(CH_2)_wCH(NR^9R^{10})CO(NR^{9'}R^{10'})$ (wherein w is 1, 2 or 3);
R^9 , $R^{9'}$, R^{10} and $R^{10'}$ are independently selected from hydrogen, hydroxy, (1-4C)alkyl (optionally substituted by 1 or 2 R^{11}), (2-4C)alkenyl, (3-7C)cycloalkyl (optionally substituted by 1 or 2 hydroxy groups), cyano((1-4C))alkyl, trihaloalkyl, aryl, heterocyclyl, heterocyclyl((1-4C)alkyl), -CO_2(1-4C)alkyl; or
R^9 and R^{10} together with the nitrogen to which they are attached, and/or $R^{9'}$ and $R^{10'}$ together with the nitrogen to which they are attached, form a 4- to 6-membered ring where the ring is optionally substituted on carbon by 1 or 2 substituents independently selected from oxo, hydroxy, carboxy, halo, nitro, cyano, carbonyl, (1-4C)alkoxy and heterocyclyl; or the ring may be optionally substituted on two adjacent carbons by –O-CH_2-O- to form a cyclic acetal wherein one or both of the hydrogens of the -O-CH_2-O- group may be replaced by a methyl;
R^{11} is independently selected from (1-4C)alkyl and hydroxy(1-4C)alkyl;
or a pharmaceutically acceptable salt or pro-drug thereof.

2. (original) A compound of the formula (1), or a pharmaceutically acceptable salt or pro-drug thereof, as claimed in claim 1, wherein A is phenylene.

3. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 ~~or claim 2~~, wherein n is 0.

4 (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 ~~any one of the preceding claims~~ wherein r is 1.

5. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 ~~any one of the preceding claims~~ wherein R^6 and R^7 are independently hydrogen or halo.

6. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 ~~any one of the preceding claims~~ wherein Y is selected from –$C(O)OR^2$, -$C(O)NR^2R^3$, -(1-4C)alkyl [optionally substituted by a substituent selected from hydroxy, (1-4C)alkoxy, -$S(O)_bR^2$ (wherein b is 0, 1 or 2), -O-$S(O)_bR^2$ (wherein b is 0, 1 or 2), -NR^2R^3, -$NR^2C(=O)R^2$ and -$SO_2NR^2R^3$], -(1-4C)alkyl$C(O)R^2$, -(1-4C)alkyl$C(O)OR^2$, -(1-4C)alkyl$OC(O)R^2$, - (1-4C)alkyl$C(O)NR^2R^3$,

-(1-4C)alkylOC(O)OR^2, -(1-4C)alkyl$N(R^2)C(O)OR^2$, -(1-4C)alkyl$N(R^2)C(O)NR^2R^3$, -(1-4C)alkylSC(O)R^2, -(1-4C)alkylOC(O)NR^2R^3, -(1-4C)alkylSO_2(2-4C)alkenyl and -SO_cR^2 (wherein c is 0, 1 or 2).

7. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 ~~any one of the preceding claims~~ wherein R^2 and R^3 are independently selected from hydrogen, heterocyclyl, -O(1-4C)alkyl, -N(1-4C)alkyl, (1-4C)alkyl [optionally substituted by 1 or 2 R^8 groups]; or an NR^2R^3 group forms a morpholine, thiomorpholine (and oxidised versions thereof), pyrrolidine, or piperidine ring and wherein the ring is optionally substituted by 1 or 2 substituents independently selected from chloro, fluoro, hydroxy and methoxy.

8. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 ~~any one of the preceding claims~~ wherein R^8 is independently selected from hydrogen, hydroxy, -C(O)$N(R^9)(R^{10})$, -NHC(O)R^9, -$COOR^9$, -CH_2OR^9, –CH_2COOR^9, –CH_2OCOR^9, aryl, heterocyclyl, and 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof.

9. (currently amended) A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 ~~any one of the preceding claims~~ wherein R^9 and R^{10} are independently selected from hydrogen, hydroxy and (1-4C)alkyl) or R^9 and R^{10} together with the nitrogen to which they are attached form a morpholine, thiomorpholine (and oxidised versions thereof), pyrrolidine, or piperidine ring.

10. (original) A pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

11-15. (cancelled)

16. (original) A process for the preparation of a compound of formula (1) as claimed in claim 1, which process comprises:
reacting an acid of the formula (2):



(2)

or an activated derivative thereof; with an amine of formula (3):



(3)

and thereafter if necessary:

i) converting a compound of the formula (1) into another compound of the formula (1);

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

17. (new) A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 wherein R^4 and R^5 are together -S-C(R^6)=C(R^7)-.

18. (new) A compound of the formula (1), or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, as claimed in claim 1 wherein both R^6 and R^7 are chloro.

19 (new) A compound of the formula (I) or a pharmaceutically acceptable salt or pro-drug thereof, wherein

A is phenylene;

n is 0;

Z is CH;

R^4 and R^5 are together –S-C(R^6)=C(R^7)- or –C(R^7)=C(R^6)-S-;

R^6 and R^7 are independently selected from hydrogen and chloro;

Y is selected from –C(O)OR^2, -C(O)NR^2R^3, -(1-4C)alkyl [optionally substituted by a substituent selected from -S(O)$_b$$R^2$ (wherein b is 0, 1 or 2), -O-S(O)$_b$$R^2$ (wherein b is 0, 1 or 2), -NR^2R^3, -NR^2C(=O)R^2 and -SO_2NR^2R^3], -(1-4C)alkylC(O)OR^2, -(1-4C)alkylOC(O)R^2, -(1-4C)alkylC(O)NR^2R^3, -(1-4C)alkylSC(O)R^2, -(1-4C)alkylSO_2(2-4C)alkenyl and -$SO_c$$R^2$ (wherein c is 0, 1 or 2);

R^2 and R^3 are independently selected from hydrogen, heterocyclyl, and (1-4C)alkyl [optionally substituted by 1 or 2 R^8 groups]; or an NR^2R^3 group forms a morpholine, thiomorpholine (and oxidised versions thereof), pyrrolidine, or piperidine ring and wherein the ring is optionally substituted by 1 or 2 substituents independently selected from chloro, fluoro, hydroxy and methoxy;

R^8 is independently selected from hydrogen, hydroxy, -C(O)N(R^9)(R^{10}), -NHC(O)R^9, -COOR^9, aryl, heterocyclyl, and 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof;
R^9 and R^{10} are independently selected from hydrogen, hydroxy and (1-4C)alkyl; or R^9 and R^{10} together with the nitrogen to which they are attached form a morpholine ring.

20 (new) A compound of the formula (I) or a pharmaceutically acceptable salt or pro-drug thereof, selected from:
Methyl (1*R*,2*R*)-2-{[(2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl]amino}indane-1-carboxylate;
(1*R*,2*R*)-2-{[(2,3-Dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl]amino}indane-1-carboxylic acid;
N-[(1*R*,2*R*)-1-(Aminocarbonyl)-2,3-dihydro-1*H*-inden-2-yl]-2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-[(1*R*,2*R*)-1-(hydroxymethyl)-2,3-dihydro-1*H*-inden-2-yl]-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-[(1*R*,2*R*)-1-(hydroxymethyl)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-((1*R*,2*R*)-1-{[(3*R*,4*S*)-3,4-dihydroxypyrrolidin-1-yl]carbonyl}-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-((1*R*,2*R*)-1-{[(2,3-dihydroxypropyl)amino]carbonyl}-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-((1*R*,2*R*)-1-{[(2-hydroxyethyl)amino]carbonyl}-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-((1*R*,2*R*)-1-{[(glycinamide]carbonyl}-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
((1*R*,2*R*)-2-{[(2,3-Dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)methyl methanesulfonate;
N-{(1*S*,2*R*)-1-[(Acetylamino)methyl]-2,3-dihydro-1*H*-inden-2-yl}-2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-{(1*S*,2*R*)-1-[(formylamino)methyl]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-{(1*S*,2*R*)-1-[(glycoloylamino)methyl]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-((1*S*,2*R*)-1-{[(methylthio)amino]methyl}-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

2-Chloro-*N*-{(1*R*,2*R*)-1-[(methylsulfinyl)methyl]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-{(1*R*,2*R*)-1-[(methylsulfonyl)methyl]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-[(1*S*,2*R*)-1-(thiomorpholin-4-ylmethyl)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-{(1*S*,2*R*)-1-[(1-oxidothiomorpholin-4-yl)methyl]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-{(1*S*,2*R*)-1-[(1,1-dioxidothiomorpholin-4-yl)methyl]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
(+/-)-*trans*-2-Chloro-*N*-[-1-(methylthio)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
(+/-)-*trans*-2,3-Dichloro-*N*-[-1-(1*H*-imidazol-2-ylthio)-2,3-dihydro-1*H*-inden-2-yl]-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
(+/-)-*trans* -2,3-Dichloro-*N*-{-1-[(4-methyl-4*H*-1,2,4-triazol-3-yl)thio]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
[((1*R*,2*R*)-2-{[(2,3-Dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)thio]acetic acid;
2,3-Dichloro-*N*-((1*R*,2*R*)-1-{[2-(dimethylamino)-2-oxoethyl]thio}-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-((1*R*,2*R*)-1-{[2-(dimethylamino)-2-oxoethyl]sulfonyl}-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
(+/-)-*trans*-(-2-{[(2-Chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)thio]acetic acid;
(+/-)-*trans*-2-Chloro-*N*-((1*R*,2*R*)-1-{[2-(dimethylamino)-2-oxoethyl]thio}-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-{(1*R*,2*R*)-1-[(2-hydroxyethyl)thio]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
(+/-)-*trans*-Methyl (-2-{[(2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)acetate;
(+/-)-*trans*-(-2-{[(2-Chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)acetic acid;
(+/-)-*trans*-2-Chloro-*N*-{-1-[2-(dimethylamino)-2-oxoethyl]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
(+/-)-*trans*-2-Chloro-*N*-[-1-(2-morpholin-4-yl-2-oxoethyl)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;

(+/-)-*trans*-2-Chloro-*N*-(-1-{2-[(2-hydroxyethyl)amino]-2-oxoethyl}-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-((1*R*,2*R*)-1-{[(2-hydroxyethyl)thio]methyl}-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-((1*R*,2*R*)-1-{[(3-hydroxypropyl)thio]methyl}-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-((1*R*,2*R*)-1-{[(2,3-dihydroxypropyl)thio]methyl}-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
N-[(1*R*,2*R*)-1-({[2-(Acetylamino)ethyl]thio}methyl)-2,3-dihydro-1*H*-inden-2-yl]-2-chloro-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
Methyl {[((1*R*,2*R*)-2-{[(2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)methyl]thio}acetate;
2-Chloro-*N*-{(1*R*,2*R*)-1-[({[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}thio)methyl]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
S-[((1*R*,2*R*)-2-{[(2-Chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)methyl] ethanethioate;
2-Chloro-*N*-((1*R*,2*R*)-1-{[(2-hydroxyethyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-((1*R*,2*R*)-1-{[(3-hydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-((1*R*,2*R*)-1-{[(2,3-dihydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
N-[(1*R*,2*R*)-1-({[2-(Acetylamino)ethyl]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-2-chloro-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-{(1*R*,2*R*)-1-[({[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}sulfinyl)methyl]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide ;
2-Chloro-*N*-{(1*R*,2*R*)-1-[({[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}sulfonyl)methyl]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-[(1*R*,2*R*)-1-({[(2*S*)-2,3-dihydroxypropyl]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-[(1*R*,2*R*)-1-({[(2*S*)-2,3-dihydroxypropyl]sulfinyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-[(1*R*,2*R*)-1-[(ethenylsulfonyl)methyl]-2,3-dihydro-1*H*-inden-2-yl]- 6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-Chloro-*N*-[(1*R*,2*R*)-1-({[2-(1*H*-imidazol-1-yl)ethyl]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;

2-Chloro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
Methyl *N*-{[((1*R*,2*R*)-2-{[1-(2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)vinyl]amino}-2,3-dihydro-1*H*-inden-1-yl)methyl]sulfonyl}glycinate;
N-{[((1*R*,2*R*)-2-{[1-(2-Chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)vinyl]amino}-2,3-dihydro-1*H*-inden-1-yl)methyl]sulfonyl}glycine;
2,3-Dichloro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-((1*R*,2*R*)-1-{[(propylamino)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-{(1*R*,2*R*)-1-[(morpholin-4-ylsulfonyl)methyl]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-Dichloro-*N*-[(1*R*,2*R*)-1-({[(2,3-dihydroxypropyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
(2*R/S*)-[((1*R*,2*R*)-2-{[(2,3-Dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)thio]propanoic acid; and
(2*R/S*)-[((1*R*,2*R*)-2-{[(2-Chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)thio]propanoic acid.

21. (new) A method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

22. (new) A method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

23. (new) A method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.